Incretin Atlas › Trials › SLIMMER-UP-SWITCH (interim)
SLIMMER-UP-SWITCH (interim)
Ecnoglutide · obesity
Design
- Molecule(s)
- Ecnoglutide
- Population
- obesity
- Phase
- 2
- Participants
- 163
- Duration
- 20 weeks
Results by arm
| Arm | Population | Weeks | n | Weight, efficacy | Weight, treatment-policy | HbA1c, pp | AE discontinuation, % | Any discontinuation, % | Nausea, % | Vomiting, % | SAE, % | SBP, mmHg | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.4 mg vs semaglutide 2.4 mg: weight -9.5 % | obesity china | 20 | 163 | — | —−12.8 % estimand not specified | — | — | — | — | — | — | — | press release |
Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.
Verbatim quotes from the source (1)
- 2.4 mg · weight_unsp · press release
the least-squares mean percentage change in body weight from baseline was -12.8% in the ecnoglutide group and -9.5% in the semaglutide group
Primary sources
How to cite this page
Medical Adviser's Group. Incretin Atlas: SLIMMER-UP-SWITCH (interim). Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/slimmer-up-switch/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.
Cite the primary publication for any single result; every value above links to it.